CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 30 enrolled
Drug / intervention
Myfortic +1 moredrug
Likely dose
Myfortic 360mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00336817
NCT00336817N/ACompleted
CompareCT.gov

A Prospective Study on the Tolerability and Efficacy of the de Novo Use of Myfortic in Liver Transplant Recipients

University of Pittsburgh·interventional·Posted Jun 14, 2006·Updated Mar 9, 2017

In Brief

A clinical study evaluating Myfortic and CellCept for Immunosuppression. Completed, enrolled 30 participants across 1 site.

Detailed Summary

The objective of this study is to compare the safety and efficacy of Myfortic with CellCept in liver transplant patients. Myfortic and CellCept are both immunosuppressive (anti-rejection) drugs. CellCept is commonly used after liver transplantation but gastrointestinal (GI) side effects are very common, sometimes necessitating in its discontinuation. Myfortic is a new drug similar to CellCept, except it is enteric-coated. Our hypothesis is that Myfortic has less GI side effects than CellCept and also has comparable effectiveness to CellCept.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsImmunosuppression
CountriesUnited States
CollaboratorsNovartis Pharmaceuticals

Timeline

N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 14, 2006
Enrollment StartNov 1, 2006
Primary CompletionNov 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 20.1 years ago

Interventions

Myforticdrug

Myfortic 360mg or 720 mg BID for 90 days

CellCeptdrug

CellCept 500mg or 1000mg BID for 90 days